Supernus Pharmaceuticals | SUPN - Ebitda



金融业
股票价格
USD 41.84
资产
USD 1.4B
现金及等价物
USD 175.88M
销售成本
USD 59M
流动资产
USD 711.22M
流动负债
USD 285.4M
债务
USD 40.17M
EBIT
USD -21.04M
EBITDA
USD 31.6M
员工
674
EPS每股收益
USD 0.35
股本和储备
USD 1.06B
销售毛利
USD 160.06M
债务利息支出
USD 2.31M
利息收入
USD 2.63M
贷款资金
USD 400.38M
市值
USD 2.33B
净收入
USD -58.37M
营业费用
USD 1.06B
营业利润
USD -21.04M
普通股股本
USD 58.16M
PE价格收益
65.37
税前利润
USD -57.65M
销售收入
USD 226.8M
销售和管理费用
USD 133.64M
股票
USD 113.24M
贸易债权人
USD 8.52M
应收帐款人
USD 211.66M


Ebitda 更改 日
Abbott USD 2.43B 844M 2026-03
ANI Pharmaceuticals USD 71.6M 6.69M 2026-06
Aurora Cannabis CAD 3.7M 14.78M 2026-03
Bristol-Myers Squibb USD 5.09B 842M 2026-06
Canopy Growth CAD -137M 134.13M 2026-03
Cara Therapeutics USD -2.39M 3.16M 2025-03
Corcept Therapeutics USD -49M 53.2M 2026-03
Eisai JPY 34.15B 34.48B 2026-06
Eli Lilly USD 12.99B 2.7B 2026-06
Novo Nordisk DKK 37.36B 2.64B 2026-06
Pacira USD 48.67M 8.43M 2026-06
Perrigo USD 141.6M 1.34B 2026-03
Pfizer USD 6.01B 18M 2026-06
Supernus Pharmaceuticals USD 31.6M 2.37M 2026-06
United Therapeutics USD 355M 11.1M 2026-06
Xeris Pharmaceuticals USD 12.33M 12.76M 2026-03